Nasdaq:BRTX
BioRestorative Therapies, Inc.
A Nasdaq-listed biotech firm specializing in regenerative medicine and cell therapy solutions for oncology and chronic disease markets.
Key Metrics
Investment Thesis
Bull Case
Investors may view BRTX as a high-risk, high-reward opportunity given its proprietary cell therapy platform and potential for breakthrough treatments in oncology. The company's ability to generate significant marketable securities proceeds suggests active fundraising and partnership activity that could fuel future commercialization milestones. If clinical trials succeed, the potential for blockbuster drug approvals could lead to substantial shareholder value creation.
Bear Case
The stock faces severe bearish pressure due to a deep retained earnings deficit of $155.7M and a consistent inability to achieve profitability over the last five years. With total liabilities matching total assets at $12.3M and minimal current assets relative to current liabilities, liquidity concerns are paramount for any potential investor. The lack of revenue growth from $0.1M in 2022/2023 to only $0.4M in 2024 indicates the company has not yet reached a sustainable commercial phase.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (BRTX) is a biotechnology company focused on developing regenerative medicine solutions, primarily serving the oncology and chronic disease markets. The company leverages its proprietary cell therapy platform to create therapies for cancer patients and individuals suffering from chronic conditions. Key revenue streams currently stem from research collaborations and early-stage product development efforts within the specialized healthcare sector.
Analysis
Management Discussion
The company reported a net loss of $9.0M in 2024, an improvement from previous years but still indicating a need for continued capital injection. Operating expenses totaling $11.9M were driven largely by general and administrative costs of $6.6M and R&D spending of $5.3M, while cash flow from operations remained negative at $8.2M despite non-cash adjustments of roughly $449k.
Industry Overview
The regenerative medicine and cell therapy industry is rapidly evolving, with significant investment flowing into oncology treatments that utilize patient-specific cells to fight cancer. Regulatory pathways for novel therapies remain complex and costly, often requiring extensive Phase I/II/III trials before market entry. Market consolidation is occurring as large pharma companies acquire promising biotech firms or form deep collaborations to access innovative platforms.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $119.8K | $145.8K | $401.0K |
| Cost of Revenue | $0 | $0 | $28.1K |
| Gross Profit | $119.8K | $145.8K | $372.9K |
| Operating Expenses | $19.1M | $15.4M | $11.9M |
| Operating Income | $-19.0M | $-15.2M | $-11.6M |
| R&D | $3.5M | $4.0M | $5.3M |
| G&A | $15.6M | $11.3M | $6.6M |
| Stock-Based Comp | $12.6M | $7.8M | $2.8M |
| D&A | $120.5K | $165.7K | $189.1K |
| Depreciation | $42.2K | $76.0K | $99.3K |
| Amortization | $78.3K | $89.7K | $89.7K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-19.0M | $-15.2M | $-11.6M |
| Income Tax | $-479.3K | $-805.3K | $-2.6M |
| Continuing Ops | $-18.5M | $-14.4M | $-9.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-18.5M | $-14.4M | $-9.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-18.5M | $-14.4M | $-9.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $15.1M | $11.4M | $11.1M |
| Cash & Equivalents | $1.7M | $884.4K | $547.9K |
| Marketable Securities | $13.1M | $10.2M | $10.2M |
| Accounts Receivable | $16.0K | $19.3K | $188.4K |
| Prepaid Expenses | $363.1K | $305.2K | $223.2K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $1.3M | $1.2M | $1.1M |
| PP&E (Net) | $261.0K | $356.1K | $362.9K |
| Intangibles | $803.4K | $713.7K | $623.9K |
| Operating Leases | $241.8K | $151.4K | — |
| Other LT Assets | $0 | $0 | $148.7K |
| Total Assets | $16.4M | $12.6M | $12.3M |
| Current Liabilities | $440.3K | $1.1M | $3.7M |
| Accounts Payable | $170.9K | $189.4K | $483.1K |
| Current Leases | $139.3K | $162.3K | — |
| Other Current Liab | $0 | $0 | $2.5M |
| Long-Term Liabilities | $162.3K | $0 | $0 |
| LT Operating Leases | $162.3K | — | — |
| Other LT Liab | $0 | — | — |
| Total Liabilities | $602.6K | $1.1M | $3.7M |
| Shareholders' Equity | $15.8M | $11.5M | $8.5M |
| Paid-In Capital | $168.5M | $178.6M | $164.2M |
| Retained Earnings | $-152.6M | $-167.1M | $-155.7M |
| Total L&E | $16.4M | $12.6M | $12.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-18.5M | $-14.4M | $-9.0M |
| Non-Cash Adjustments | $12.7M | $7.6M | $449.4K |
| Working Capital Changes | $-110.1K | $406.2K | $299.7K |
| Cash from Operations | $-5.9M | $-6.4M | $-8.2M |
| Capital Expenditures | $265.2K | $171.0K | $106.2K |
| Cash from Investing | $-13.5M | $3.3M | $514.5K |
| Cash from Financing | $0 | $2.4M | $7.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-19.4M | $-826.8K | $-336.5K |
| Beginning Cash | $21.0M | $1.7M | $884.4K |
| Ending Cash | $1.7M | $886.9K | $547.9K |
Frequently Asked Questions
How does BioRestorative Therapies, Inc. make money?
Proprietary Cell Therapy Platform, Oncology Therapeutics Development, Chronic Disease Solutions
What are the main risks for BRTX?
Significant ongoing net losses of $9.0M in 2024 requiring substantial future capital raising, limited current revenue base with minimal commercial sales history, potential for regulatory delays in obtaining FDA approval for novel cell therapies, and dilution risks from frequent equity financing needs to sustain operations.
What is BRTX's competitive advantage?
Proprietary cell reprogramming technology offering novel therapeutic mechanisms, strategic partnerships with major pharmaceutical entities to share development risk, and a focused pipeline targeting high-need unmet medical requirements in oncology.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.